

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See M.P.E.P. § 324.

Patent
Attorney's Docket No. 032751-073

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Rainer BISCHOFF et al.) Group Art Unit: 1632
Application No.: 10/021,421) Examiner: R. Schnizer
Filed: December 19, 2001) Confirmation No.: 3280
For: LIPID COMPOUNDS AND)
COMPOSITIONS CONTAINING THEM)
WHICH CAN BE USED FOR THE)
TRANSFER OF AT LEAST ONE)
ACTIVE SUBSTANCE, IN)
PARTICULAR A POLYNUCLEOTIDE,)
INTO A TARGET CELL AND USE IN)
GENE THERAPY)

RECEIVED
TECH CENTER 1600/2900
03 APR 16 PH 1:12

RECEIVED
APR 18 2003
TECH CENTER 1600/2900

VIA HAND-CARRY TO EXAMINER
Group Art Unit: 1632

SUBMISSION OF TERMINAL DISCLAIMER
AND STATEMENT UNDER 37 C.F.R. § 3.73(b)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Attached please find an executed Terminal Disclaimer and Statement Under 37 C.F.R. § 3.73(b) in connection with the application identified above.

A check for [] \$55.00 (2814) [] \$110.00 (1814) to cover the requisite Government fee is also attached. The Commissioner is authorized to charge any fees that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Susan M. Dadio
Susan M. Dadio
Registration No. 40,373

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: April 16, 2003

Attorney's Docket No. 032751-073

STATEMENT UNDER 37 C.F.R. § 3.73(b)

Applicant/Patent Owner: Rainer BISCHOFF et al.

Application No./Patent No.: 10/021,421

Filed/Issue Date: December 19, 2001

Entitled: LIPID COMPOUNDS AND COMPOSITIONS CONTAINING SAME USED FOR THE TRANSFER OF AT LEAST AN ACTIVE SUBSTANCE, IN PARTICULAR A POLYNUCLEOTIDE INTO A TARGET CELL AND THERAPEUTIC USE

TRANSGENE S.A.
(Name of Assignee)

a corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or
2. an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 010079, Frame 0563, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.


Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

NOTE: A separate copy [i.e., the original assignment document or a true copy of the original document] must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

Date: 16 April 2003


Signature

JEAN-FRANCOIS CARMIER

**Typed or printed name
Chief Executive Officer**

Title